Gilead Acquires Cancer Biotech Tubulis for $5 Billion
Gilead Sciences is set to acquire Tubulis, a cancer biotechnology company, for $5 billion. The acquisition will bolster Gilead's oncology pipeline and expand its research and development capabilities in cancer treatment.